The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Exploratory biomarker analysis for predicting treatment effects of aflibercept in the VELOUR trial.
 
Ting Pu
No Relationships to Disclose
 
Allyson Peddle
No Relationships to Disclose
 
Pratyaksha Wirapati
No Relationships to Disclose
 
Yourae Hong
No Relationships to Disclose
 
Leslie Samuel
No Relationships to Disclose
 
Jayesh Desai
Consulting or Advisory Role - Amgen (Inst); Axelia Oncology; Bayer; BeiGene; Boehringer Ingelheim; Daiichi Sankyo Europe GmbH; Ellipses Pharma; GlaxoSmithKline; Incyte; Merck KGaA; Novartis; Pfizer; Pierre Fabre; Roche/Genentech
Research Funding - Amgen (Inst); AstraZeneca/MedImmune (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Roche (Inst)
 
Maigo Riener
No Relationships to Disclose
 
Zacharenia (Zenia) Saridaki
No Relationships to Disclose
 
David Cunningham
Stock and Other Ownership Interests - OVIBIO
Consulting or Advisory Role - OVIBIO
Research Funding - 4SC (Inst); Bayer (Inst); Clovis Oncology (Inst); Leap Oncology (Inst); Lilly (Inst); MedImmune (Inst); Roche (Inst)
 
Sabine Tejpar
Honoraria - Merck Serono; Regeneron
Consulting or Advisory Role - Bayer; Boehringer Ingelheim; Merck Serono; Regeneron; Roche/Genentech
Speakers' Bureau - Bristol-Myers Squibb; Merck Serono; MSD; Roche; Sanofi
Travel, Accommodations, Expenses - Amgen; Bayer; Merck Serono; Roche; Sanofi
 
Petros Tsantoulis
No Relationships to Disclose